Fig. 9.

RGFP-966 rescues AD-like pathology in iPSC-derived AD-patient primary neurons. (A) RGFP-966 decreased HDAC3 activity in iPSC-AD neurons. (B) RGFP-966 decreased Aβ_1–42 in iPSC-AD neurons. (C) In response to 10 μM RGFP-966, tau acetylation at lysine 280 (Ac-tau K-280) decreased significantly in patient 1, with no effect on tau phosphorylation at Ser²⁰² and Ser³⁹⁶. (D) In response to 10 μM RGFP-966, tau phosphorylation at Ser²⁰² and Ser³⁹⁶ decreased significantly in patient 2, with no effect on tau acetylation. Two-tailed unpaired t-test was used for analysis. The graphs represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001; n = 6.